Literature DB >> 19455106

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.

Guadalupe Garcia-Tsao1, Joseph K Lim, Joseph Lim.   

Abstract

Cirrhosis represents the end stage of any chronic liver disease. Hepatitis C and alcohol are currently the main causes of cirrhosis in the United States. Although initially cirrhosis is compensated, it eventually becomes decompensated, as defined by the presence of ascites, variceal hemorrhage, encephalopathy, and/or jaundice. These management recommendations are divided according to the status, compensated or decompensated, of the cirrhotic patient, with a separate section for the screening, diagnosis, and management of hepatocellular carcinoma (HCC), as this applies to patients with both compensated and decompensated cirrhosis. In the compensated patient, the main objective is to prevent variceal hemorrhage and any practice that could lead to decompensation. In the decompensated patient, acute variceal hemorrhage and spontaneous bacterial peritonitis are severe complications that require hospitalization. Hepatorenal syndrome is also a severe complication of cirrhosis but one that usually occurs in patients who are already in the hospital and, as it represents an extreme of the hemodynamic alterations that lead to ascites formation, it is placed under treatment of ascites. Recent advances in the pathophysiology of the complications of cirrhosis have allowed for a more rational management of cirrhosis and also for the stratification of patients into different risk groups that require different management. These recommendations are based on evidence in the literature, mainly from randomized clinical trials and meta-analyses of these trials. When few or no data exist from well-designed prospective trials, emphasis is given to results from large series and consensus conferences with involvement of recognized experts. A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19455106     DOI: 10.1038/ajg.2009.191

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  73 in total

1.  Liver: diuretic agents for ascites: joining forces from the start?

Authors:  Pere Ginès
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 46.802

2.  Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.

Authors:  Yolanda Rodriguez Villalvazo; Jennifer S McDanel; Lauren A Beste; Antonio J Sanchez; Mary Vaughan-Sarrazin; David A Katz
Journal:  Health Serv Res       Date:  2019-11-25       Impact factor: 3.402

3.  Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Christine M Schubert; Douglas M Heuman; James B Wade; Douglas P Gibson; Allyne Topaz; Kia Saeian; Muhammad Hafeezullah; Debulon E Bell; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Melanie B White; Arun J Sanyal
Journal:  Gastroenterology       Date:  2010-02-20       Impact factor: 22.682

4.  Toward the Effective Co-management of Patients with Cirrhosis by Primary Care Providers and Specialists.

Authors:  Rena K Fox
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

5.  Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.

Authors:  Christopher Kniese; Khalil Diab; Marwan Ghabril; Gabriel Bosslet
Journal:  Chest       Date:  2018-07-07       Impact factor: 9.410

Review 6.  Multidisciplinary management of patients with cirrhosis: a need for care coordination.

Authors:  Jessica L Mellinger; Michael L Volk
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-06       Impact factor: 11.382

Review 7.  Decorin-TGFβ axis in hepatic fibrosis and cirrhosis.

Authors:  Kornélia Baghy; Renato V Iozzo; Ilona Kovalszky
Journal:  J Histochem Cytochem       Date:  2012-01-19       Impact factor: 2.479

8.  Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis.

Authors:  Xing-Shun Qi; Ming Bai; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

10.  Underestimation of liver-related mortality in the United States.

Authors:  Sumeet K Asrani; Joseph J Larson; Barbara Yawn; Terry M Therneau; W Ray Kim
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.